About: COVID‐19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID‐19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID‐19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients
Creator	Bhattacharya, Manojit Chakraborty, Chiranjib Lee, Sang-Soo Ranjan Sharma, Ashish Sharma, Garima Agoramoorthy, Govindasamy Chakraborty,
Source	Medline; PMC; WHO
abstract	COVID‐19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID‐19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS‐CoV‐2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved.
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1002/jmv.26078
bibo:pmid	32462717
has license	no-cc
sha1sum (hex)	bd8f26d1794d714d1fc696788609cb08109f6db2
schema:url	https://doi.org/10.1002/jmv.26078
resource representing a document's title	COVID‐19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients
has PubMed Central identifier	PMC7283789
has PubMed identifier	32462717
schema:publication	J Med Virol
resource representing a document's body	covid:bd8f26d1794d714d1fc696788609cb08109f6db2#body_text
is schema:about of	named entity 'antagonists' named entity 'receptor' named entity 'infected' named entity 'LOOK' named entity 'CYTOKINE STORM' named entity 'therapies' named entity 'therapy' named entity 'receptor antagonist' named entity 'IL6' named entity 'cytokine storm' named entity 'IL6' named entity 'cytokine storm' named entity 'IL6' named entity 'cytokine storm' named entity 'cytokine storm syndrome' named entity 'SARS-CoV-2' named entity 'respiratory muscles' named entity 'respiratory failure' named entity 'oxygen diffusion' named entity 'cytokine storm syndrome' named entity 'inflammatory' named entity 'Clinical trials' named entity 'cytokines' named entity 'receptor antagonist' named entity 'humanized monoclonal antibody' named entity 'antagonist' named entity 'IL6' named entity 'Sarilumab' named entity 'humanized monoclonal antibody' named entity 'IL6R' named entity 'COVID-19' named entity 'COVID-19' named entity 'molecular mechanism' named entity 'antagonist' named entity 'COVID' named entity 'clinical trial' named entity 'IL-6R' named entity 'IL-6' named entity 'China' named entity 'Tocilizumab' named entity 'IL-6R' named entity 'SARS-CoV-2' named entity 'cytokine storm' named entity 'SARS-CoV-2' named entity 'Sarilumab' named entity 'antagonist' named entity 'IL-6' named entity 'serum' named entity 'Tocilizumab' named entity 'cytokine storm syndrome' named entity 'COVID' named entity 'COVID' named entity 'IL-6' named entity 'cytokine storm' named entity 'IL-6R' named entity 'IL6R' named entity 'IL6' named entity 'antagonist' named entity 'receptor antagonist' named entity 'cytokine storm syndrome' named entity 'clinical trial' named entity 'IL6' covid:arg/bd8f26d1794d714d1fc696788609cb08109f6db2 named entity 'humanized' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'monoclonal antibodies' named entity 'tocilizumab' named entity 'cytokine storm' named entity 'COVID-19' named entity 'receptor antagonist' named entity 'receptor antagonists' named entity 'sarilumab' named entity 'IL6R' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software